Board of Directors
Dr John M Hall
Dr Hall previously served at Quintiles Limited as General Manager, and was responsible for growing European non-clinical operations. Latterly, he was responsible for relationships with the company’s European mid-sized and international Japanese accounts. Additional leadership positions held include Owner and Managing Director of Pharmacophore, a pharmaceutical and biotechnology product development management consulting firm, Senior Director of European Preclinical Development for GD Searle, and Manager of Marketing Development for Monsanto Company’s Health Care Division.
He has a PhD in pharmacology and initially worked in laboratories in Roche UK and at Inveresk Research International, eventually leading the Pharmacology and Consumer Product Evaluation teams. He was appointed Chairman of TMRI (Translational Medicine Research Institute), Glasgow, Scotland. He is a member of the Scottish Life Sciences Advisory Group and the NHS Scotland Chief Scientist Committee. He has been an Honorary Lecturer in Management Studies at St. Andrew’s University.
Mr Adam Christie
Adam has a broad background in the pharmaceutical and biotechnology industry. He is a business developer and marketer with direct experience of drug and device development and the capital markets. Adam is CEO of Calcivis, a dental imaging business he started in 2011. Previously, as Chief Business Officer at PowderMed, he led business development and commercial strategy which culminated in the successful sale of the company to Pfizer in late 2006, two and a half years after a series ‘A’ venture funding round.
His earlier career included roles in business development, marketing and R&D at PPL Therapeutics, GlaxoSmithKline, Abbott Laboratories and Schering AG, and as a City analyst at ABN Amro Hoare Govett. His educational background includes a BSc in Pharmacology from Southampton University and an MBA from Warwick Business School.
Mr Douglas Thomson
Mr Douglas Thomson has significant international experience as CEO, Chairman, NXD and BD Director. He has led executive teams ensuring rapid value creation at companies such as 4D Pharma and AvantiCell Science. He has executed multiple commercial deals with biotechnology and pharmaceutical companies.
Mr John Waddell
John Waddell stepped down as CEO of Archangel Investors Ltd, who have led each funding round in MGB Biopharma to date, in September 2015 after 10 years at the helm. John is a lawyer with wide experience in industry and corporate finance in the UK and overseas. He continues to advise Archangels and is on the boards of IndigoLighthouse Group Limited, NCTech Limited and Northern 3 VCT PLC. He is also on the advisory boards of Amadeus & Angels Seed Fund and Seraphim Capital.
Mr Ken Fyvie
Ken has 40 years’ experience of the life sciences sector accumulated through working in the pharmaceutical industry in sales and marketing roles, in investment research of the sector and related corporate finance, and as a member of the management group at PA Consulting Group. At PA his activities emphasised business strategy, new product development and commercialisation, business performance improvement and organisational development. During his time at PA, Ken worked with many of the companies in the sector, including Big Pharma, SMEs / Specialists and start-ups.
Since retiring from PA in late 2013, Ken has worked independently as a consultant, and collaborated with several providers of specialist services to the life sciences sector.
In early 2015 Ken joined the board of Cytomos Ltd., a young company developing a novel approach to biological cell analysis, where his understanding of the market, product development experience and management insights have contributed to Cytomos’ progress. Ken joined the board of MGB Biopharma as Chairman in July 2016 where his experience in drug development, of ant-infectives in particular, and of business management, will provide an assist to the executive team and board.